A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction
Tekijät: Airaksinen, K. E. Juhani; Teppo, Konsta; Vasankari, Tuija; Paana, Tuomas; Junes, Helea; Salonen, Selma; Tuominen, Tuulia; Simonen, Sara; Strandberg, Marjatta; Hellman, Tapio; Linko‐Parvinen, Anna; Pallari, Hanna‐Mari; Jaakkola, Samuli; Wittfooth, Saara
Kustantaja: Ovid Technologies (Wolters Kluwer Health)
Julkaisuvuosi: 2026
Lehti: Journal of the American Heart Association
Artikkelin numero: e044092
Vuosikerta: 15
Numero: 6
eISSN: 2047-9980
DOI: https://doi.org/10.1161/JAHA.125.044092
Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla
Julkaisukanavan avoimuus : Kokonaan avoin julkaisukanava
Verkko-osoite: https://doi.org/10.1161/jaha.125.044092
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/515754724
Rinnakkaistallenteen lisenssi: CC BY NC ND
Rinnakkaistallennetun julkaisun versio: Kustantajan versio
Background
Elevated troponin levels are a frequent finding in patients presenting with atrial fibrillation or atrial flutter (AF) to the emergency department but are seldom caused by myocardial infarction (MI). The current high‐sensitivity cTnT (cardiac troponin T) assay measures both the intact and highly fragmented cTnT forms (total cTnT) and detects cTnT elevations in conditions causing myocardial injury or MI without distinction between the 2.
MethodsThe SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin) study included 521 consecutive patients with AF only and 188 patients with MI only (139 Type 1 MI), all with a total cTnT value ≥14 ng/L at emergency department admission. Intact and long forms of cTnT (long cTnT) were analyzed from the first plasma samples using a novel immunoassay. The diagnostic performance of long cTnT and total cTnT assays was compared in these cases with elevated total cTnT.
ResultsLong cTnT was superior to total cTnT in discriminating troponin elevations in patients with MI from those in patients with AF (area under the curve for type 1 MI: 0.879 versus 0.783; for any MI: 0.864 versus 0.779; both P<0.001) when measured from the first blood sample without a significant effect of sex, age, estimated glomerular filtration rate, or total cTnT <200 ng/L. The difference in long cTnT levels was most notable in patients presenting within 12 hours of symptom onset.
ConclusionsThe long cTnT immunoassay shows that the troponin release in AF is composed mainly of smaller troponin fragments. This novel test holds promise that measuring long cTnT forms could help to separate troponin elevations caused by AF from those of acute Type 1 MI from a single sample with better accuracy than the commercial high‐sensitivity cTnT test.
Ladattava julkaisu This is an electronic reprint of the original article. |
Julkaisussa olevat rahoitustiedot:
Research funding from Business Finland, Research grants from the Finnish Foundation for Cardiovascular Research. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; and decision to submit the article for publication.